CLOs on the Move

Oncternal

www.oncternal.com

 
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.oncternal.com
  • 12230 El Camino Real Suite 300
    San Diego, CA USA 92130
  • Phone: 858.434.1113

Executives

Name Title Contact Details
Chase Leavitt
General Counsel Profile

Similar Companies

Advanced Accelerator Applications

Advanced Accelerator Applications is a pharmaceutical group specialized in the field of nuclear medicine.

Metrics

Metrics provides pharmaceutical product development including pre-formulation studies, formulation development, clinical trial batch manufacturing and clinical trial batch packaging and labeling for non-sterile dosage forms. In addition, Metrics

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.

TearClear

TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development.

Diva Pharmaceuticals

Diva Pharmaceuticals is a Upper Saddle River, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.